메뉴 건너뛰기




Volumn 109, Issue 29-30, 2012, Pages 495-501

The therapeutic potential of cannabis and cannabinoids;Das therapeutische Potenzial von Cannabis und Cannabinoiden

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABIS; DRONABINOL; NABILONE;

EID: 84900812931     PISSN: 18660452     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2012.0495     Document Type: Article
Times cited : (273)

References (143)
  • 6
    • 84902810936 scopus 로고    scopus 로고
    • Stellungnahme der Bundesärztekammer, der Kassenärztlichen Bundesvereinigung und der Arzneimittelkommission der deutschen Ärzteschaft zu den Anträgen der Fraktion Bündnis 90/Die Grünen, und der Fraktion Die Linke "Cannabis zur medizinischen Behandlung freigeben" vom 25.06.2008. Ausschussdrucksache 16(14)0420(9). Deutscher Bundestag, Ausschuss für Gesundheit
    • Stellungnahme der Bundesärztekammer, der Kassenärztlichen Bundesvereinigung und der Arzneimittelkommission der deutschen Ärzteschaft zu den Anträgen der Fraktion Bündnis 90/Die Grünen "Medizinische Verwendung von Cannabis erleichtern" vom 27. 11. 2007 und der Fraktion Die Linke "Cannabis zur medizinischen Behandlung freigeben" vom 25.06.2008. Ausschussdrucksache 16(14)0420(9). Deutscher Bundestag, Ausschuss für Gesundheit.
    • (2007) Medizinische Verwendung von Cannabis Erleichtern , vol.27 , Issue.11
  • 8
    • 33947489961 scopus 로고
    • Isolation, structure, and partial synthesis of an active constituent of hashish
    • Gaoni Y, Mechoulam R: Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964; 86: 1646-7.
    • (1964) J Am Chem Soc , vol.86 , pp. 1646-1647
    • Gaoni, Y.1    Mechoulam, R.2
  • 9
    • 65449146377 scopus 로고    scopus 로고
    • Emerging strategies for exploiting cannabinoid receptor agonists as medicines
    • Pertwee RG: Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 2009; 156: 397-411.
    • (2009) Br J Pharmacol , vol.156 , pp. 397-411
    • Pertwee, R.G.1
  • 12
    • 78650120798 scopus 로고    scopus 로고
    • Cannabinoid receptors and their ligands: Beyond CB1 and CB2
    • Pertwee RG, Howlett AC, Abood ME, et al.: Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev 2010; 62: 588-631.
    • (2010) Pharmacol Rev , vol.62 , pp. 588-631
    • Pertwee, R.G.1    Howlett, A.C.2    Abood, M.E.3
  • 13
    • 77954175115 scopus 로고    scopus 로고
    • Cannabinoid activation of peroxisome proliferator-activated receptors: Potential for modulation of inflammatory disease
    • O'Sullivan SE, Kendall DA: Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease. Immunobiology 2010; 215: 611-6.
    • (2010) Immunobiology , vol.215 , pp. 611-616
    • O'sullivan, S.E.1    Kendall, D.A.2
  • 14
    • 34548498839 scopus 로고    scopus 로고
    • The toxicology of cannabis and cannabis prohibition
    • Grotenhermen F: The toxicology of cannabis and cannabis prohibi - tion. Chem Biodivers 2007; 4: 1744-69.
    • (2007) Chem Biodivers , vol.4 , pp. 1744-1769
    • Grotenhermen, F.1
  • 17
    • 34447619511 scopus 로고    scopus 로고
    • Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review
    • Moore TH, Zammit S, Lingford-Hughes A, et al.: Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007; 370: 319-28.
    • (2007) Lancet , vol.370 , pp. 319-328
    • Moore, T.H.1    Zammit, S.2    Lingford-Hughes, A.3
  • 18
    • 38649131428 scopus 로고    scopus 로고
    • Daily cannabis use: A novel risk factor of steatosis severity in patients with chronic hepatitis C
    • Hézode C, Zafrani ES, Roudot-Thoraval F, et al.: Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterology 2008; 134: 432-9.
    • (2008) Gastroenterology , vol.134 , pp. 432-439
    • Hézode, C.1    Zafrani, E.S.2    Roudot-Thoraval, F.3
  • 19
    • 36749069565 scopus 로고    scopus 로고
    • A within-subject comparison of withdrawal symptoms during abstinence from cannabis, tobacco, and both substances
    • Vandrey RG, Budney AJ, Hughes JR, Liguori A: A within-subject comparison of withdrawal symptoms during abstinence from cannabis, tobacco, and both substances. Drug Alcohol Depend 2008; 92: 48-54.
    • (2008) Drug Alcohol Depend , vol.92 , pp. 48-54
    • Vandrey, R.G.1    Budney, A.J.2    Hughes, J.R.3    Liguori, A.4
  • 20
    • 8544278893 scopus 로고    scopus 로고
    • Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia
    • Beal JE, Olson R, Lefkowitz L, et al.: Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage 1997; 14: 7-14.
    • (1997) J Pain Symptom Manage , vol.14 , pp. 7-14
    • Beal, J.E.1    Olson, R.2    Lefkowitz, L.3
  • 21
    • 0037040369 scopus 로고    scopus 로고
    • The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir
    • Kosel BW, Aweeka FT, Benowitz NL, et al.: The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS 2002; 16: 543-50.
    • (2002) AIDS , vol.16 , pp. 543-550
    • Kosel, B.W.1    Aweeka, F.T.2    Benowitz, N.L.3
  • 22
    • 34147104462 scopus 로고    scopus 로고
    • Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel
    • Engels FK, de Jong FA, Sparreboom A, et al.: Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel. Oncologist 2007; 12: 291-300.
    • (2007) Oncologist , vol.12 , pp. 291-300
    • Engels, F.K.1    De Jong, F.A.2    Sparreboom, A.3
  • 23
    • 0345668786 scopus 로고    scopus 로고
    • Interactions of marihuana and 9-THC with other drugs
    • Nahas G, Sutin KM, Harvey DJ, Agurell S (eds.). Totowa, NJ: Humana Press
    • Hollister LE: Interactions of marihuana and 9-THC with other drugs. In: Nahas G, Sutin KM, Harvey DJ, Agurell S (eds.): Marihuana and Medicine. Totowa, NJ: Humana Press 1999: 273-7.
    • (1999) Marihuana and Medicine , pp. 273-277
    • Hollister, L.E.1
  • 25
    • 0037076468 scopus 로고    scopus 로고
    • Safety, tolerability, and efficacy of orally administered cannabinoids in MS
    • Killestein J, Hoogervorst EL, Reif M, et al.: Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 2002; 58: 1404-7.
    • (2002) Neurology , vol.58 , pp. 1404-1407
    • Killestein, J.1    Hoogervorst, E.L.2    Reif, M.3
  • 26
    • 0242654882 scopus 로고    scopus 로고
    • Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomised placebo-controlled trial
    • Zajicek J, Fox P, Sanders H, et al.: Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003; 362: 1517-26.
    • (2003) Lancet , vol.362 , pp. 1517-1526
    • Zajicek, J.1    Fox, P.2    Sanders, H.3
  • 27
    • 70449533773 scopus 로고    scopus 로고
    • Lack of effect of cannabisbased treatment on clinical and laboratory measures in multiple sclerosis
    • Centonze D, Mori F, Koch G, et al.: Lack of effect of cannabisbased treatment on clinical and laboratory measures in multiple sclerosis. Neurol Sci 2009; 30: 531-4.
    • (2009) Neurol Sci , vol.30 , pp. 531-534
    • Centonze, D.1    Mori, F.2    Koch, G.3
  • 28
    • 0019604277 scopus 로고
    • Treatment of human spasticity with 9-tetrahydrocannabinol
    • Petro DJ, Ellenberger C: Treatment of human spasticity with 9-tetrahydrocannabinol. J Clin Pharmacol 1981; (Suppl 21): 413-6.
    • (1981) J Clin Pharmacol , Issue.SUPPL. 21 , pp. 413-416
    • Petro, D.J.1    Ellenberger, C.2
  • 30
    • 28144454955 scopus 로고    scopus 로고
    • Cannabinoids in multiple sclerosis (CAMS) study: Safety and efficacy data for 12 months follow up
    • Zajicek JP, Sanders HP, Wright DE, et al.: Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 2005; 76: 1664-9.
    • (2005) J Neurol Neurosurg Psychiatry , vol.76 , pp. 1664-1669
    • Zajicek, J.P.1    Sanders, H.P.2    Wright, D.E.3
  • 31
    • 4344571664 scopus 로고    scopus 로고
    • Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled, crossover study
    • Vaney C, Heinzel-Gutenbrunner M, Jobin P, et al.: Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Multiple Sclerosis 2004; 10: 417-24.
    • (2004) Multiple Sclerosis , vol.10 , pp. 417-424
    • Vaney, C.1    Heinzel-Gutenbrunner, M.2    Jobin, P.3
  • 32
    • 4344582253 scopus 로고    scopus 로고
    • Do cannabis- based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients
    • Wade DT, Makela P, Robson P, House H, Bateman C: Do cannabis- based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004; 10: 434-41.
    • (2004) Mult Scler , vol.10 , pp. 434-441
    • Wade, D.T.1    Makela, P.2    Robson, P.3    House, H.4    Bateman, C.5
  • 33
    • 33745025055 scopus 로고    scopus 로고
    • Longterm use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis
    • Wade DT, Makela PM, House H, Bateman C, Robson P: Longterm use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 2006; 12: 639-45.
    • (2006) Mult Scler , vol.12 , pp. 639-645
    • Wade, D.T.1    Makela, P.M.2    House, H.3    Bateman, C.4    Robson, P.5
  • 34
    • 33847766180 scopus 로고    scopus 로고
    • For the Sativex Spasticity in MS Study Group: Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis
    • Collin C, Davies P, Mutiboko IK, Ratcliffe S, for the Sativex Spasticity in MS Study Group: Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurology 2007; 14: 290-6.
    • (2007) Eur J Neurology , vol.14 , pp. 290-296
    • Collin, C.1    Davies, P.2    Mutiboko, I.K.3    Ratcliffe, S.4
  • 35
    • 63549096654 scopus 로고    scopus 로고
    • Cannabinoid-induced effects on the nociceptive system: A neurophysiological study in patients with secondary progressive multiple sclerosis
    • Conte A, Bettolo CM, Onesti E, et al.: Cannabinoid-induced effects on the nociceptive system: a neurophysiological study in patients with secondary progressive multiple sclerosis. Eur J Pain 2009; 13: 472-7.
    • (2009) Eur J Pain , vol.13 , pp. 472-477
    • Conte, A.1    Bettolo, C.M.2    Onesti, E.3
  • 36
    • 79953822342 scopus 로고    scopus 로고
    • A randomized, doubleblind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis
    • Novotna A, Mares J, Ratcliffe S, et al.: A randomized, doubleblind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 2011; 18: 1122-31.
    • (2011) Eur J Neurol , vol.18 , pp. 1122-1131
    • Novotna, A.1    Mares, J.2    Ratcliffe, S.3
  • 38
    • 34547623372 scopus 로고    scopus 로고
    • The treatment of spasticity with delta-9-tetrahydrocannabinol in persons with spinal cord injury
    • Hagenbach U, Luz S, Ghafoor N, et al.: The treatment of spasticity with delta-9-tetrahydrocannabinol in persons with spinal cord injury. Spinal Cord 2007; 45: 551-62.
    • (2007) Spinal Cord , vol.45 , pp. 551-562
    • Hagenbach, U.1    Luz, S.2    Ghafoor, N.3
  • 39
    • 77951262920 scopus 로고    scopus 로고
    • A randomized, double-blinded, crossover pilot study assessing the effect of nabilone on spasticity in persons with spinal cord injury
    • Pooyania S, Ethans K, Szturm T, Casey A, Perry D: A randomized, double-blinded, crossover pilot study assessing the effect of nabilone on spasticity in persons with spinal cord injury. Arch Phys Med Rehabil 2010; 91: 703-7.
    • (2010) Arch Phys Med Rehabil , vol.91 , pp. 703-707
    • Pooyania, S.1    Ethans, K.2    Szturm, T.3    Casey, A.4    Perry, D.5
  • 40
    • 84902824406 scopus 로고
    • Tetrahydrocannabinol (THC) plus prochlorperazine (PCZ) for refractory nausea and vomiting (N/V)
    • Artim R, DiBella N: Tetrahydrocannabinol (THC) plus prochlorperazine (PCZ) for refractory nausea and vomiting (N/V). Proc Am Soc Clin Oncol 1983; 2: 84.
    • (1983) Proc Am Soc Clin Oncol , vol.2 , pp. 84
    • Artim, R.1    Dibella, N.2
  • 41
    • 0018653395 scopus 로고
    • Delta-9-tetrahydrocannabinol as an antiemetics in cancer patients receiving high-dose methotrexate
    • Chang AE, Shiling DJ, Stillman RC, Goldberg NH, Seipp CA, Barofsky I: Delta-9-tetrahydrocannabinol as an antiemetics in cancer patients receiving high-dose methotrexate. Ann Int Med 1979; 91: 819-24.
    • (1979) Ann Int Med , vol.91 , pp. 819-824
    • Chang, A.E.1    Shiling, D.J.2    Stillman, R.C.3    Goldberg, N.H.4    Seipp, C.A.5    Barofsky, I.6
  • 42
    • 0019460943 scopus 로고
    • A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy
    • Chang AE, Shiling DJ, Stillman RC, et al.: A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. Cancer 1981; 47: 1746-51.
    • (1981) Cancer , vol.47 , pp. 1746-1751
    • Chang, A.E.1    Shiling, D.J.2    Stillman, R.C.3
  • 43
    • 0018828574 scopus 로고
    • The antiemetic activity of tetrahydrocanabinol versus metoclopramide and thiethylperazine in patients undergoing cancer chemotherapy
    • Colls BM, Ferry DG, Gray AJ, Harvey VJ, McQueen EG: The antiemetic activity of tetrahydrocanabinol versus metoclopramide and thiethylperazine in patients undergoing cancer chemotherapy. N Z Med J 1980; 91: 449-51.
    • (1980) N Z Med J , vol.91 , pp. 449-451
    • Colls, B.M.1    Ferry, D.G.2    Gray, A.J.3    Harvey, V.J.4    McQueen, E.G.5
  • 44
    • 0018793008 scopus 로고
    • Amelioration of cancer chemotherapy-induced nausea and vomiting by Δ9-tetrahydrocannabinol
    • Ekert H, Waters KD, Jurk KH, Mobilia J, Loughnan P: Amelioration of cancer chemotherapy-induced nausea and vomiting by Δ9- tetrahydrocannabinol. Med J Aust 1979; 2: 657-9.
    • (1979) Med J Aust , vol.2 , pp. 657-659
    • Ekert, H.1    Waters, K.D.2    Jurk, K.H.3    Mobilia, J.4    Loughnan, P.5
  • 45
    • 0018611443 scopus 로고
    • Delta-9-tetrahydrocannabinol as an antiemetics for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo
    • Frytak S, Moertel CG, O'Fallon JR, Rubin J, Creagan ET, O'Connnell MJ: Delta-9-tetrahydrocannabinol as an antiemetics for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. Ann Int Med 1979; 91: 825-30.
    • (1979) Ann Int Med , vol.91 , pp. 825-830
    • Frytak, S.1    Moertel, C.G.2    O'fallon, J.R.3    Rubin, J.4    Creagan, E.T.5    O'connnell, M.J.6
  • 46
    • 0021356476 scopus 로고
    • Antiemetic therapy: A review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol
    • Gralla RJ, Tyson LB, Bordin LA, Clark RA, Kelsen DP, Kris MG: Antiemetic therapy: a review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol. Can Treat Rep 1984; 68: 163-72.
    • (1984) Can Treat Rep , vol.68 , pp. 163-172
    • Gralla, R.J.1    Tyson, L.B.2    Bordin, L.A.3    Clark, R.A.4    Kelsen, D.P.5    Kris, M.G.6
  • 47
    • 0018668244 scopus 로고
    • Δ9-tetrahydrocannabinol (THC) as an antiemetic in patients treated with cancer chemotherapy; A double-blind crossover trial against placebo
    • Kluin-Nelemans JC, Nelemans FA, Meuwissen OJATh, Maes RAA: Δ9-tetrahydrocannabinol (THC) as an antiemetic in patients treated with cancer chemotherapy; a double-blind crossover trial against placebo. Vet Hum Toxicol 1979; 21: 338-40.
    • (1979) Vet Hum Toxicol , vol.21 , pp. 338-340
    • Kluin-Nelemans, J.C.1    Nelemans, F.A.2    Meuwissen Th., O.J.A.3    Maes, R.A.A.4
  • 48
    • 0026212048 scopus 로고
    • Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting
    • Lane M, Vogel CL, Ferguson J, Krasnow S, Saiers JL, Hamm J: Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. J Pain Sym Manag 1991; 6: 352-9.
    • (1991) J Pain Sym Manag , vol.6 , pp. 352-359
    • Lane, M.1    Vogel, C.L.2    Ferguson, J.3    Krasnow, S.4    Saiers, J.L.5    Hamm, J.6
  • 49
    • 0003376856 scopus 로고
    • Randomized double blind comparison of delta-9-tetrahydroicannabinol (THC) and marijuana as chemotherapy antiemetics
    • Levitt M, Faiman C, Hawks R, Wilson A: Randomized double blind comparison of delta-9-tetrahydroicannabinol (THC) and marijuana as chemotherapy antiemetics. Proc Am Soc Clin Oncol 1984; 3: 91.
    • (1984) Proc Am Soc Clin Oncol , vol.3 , pp. 91
    • Levitt, M.1    Faiman, C.2    Hawks, R.3    Wilson, A.4
  • 50
    • 84902763519 scopus 로고
    • Dose vs response of tetrahydroannabinol (THC) vs prochlorperazine as chemotherapy antiemetics
    • Levitt M, Wilson A, Bowman D, Faiman C, Kemel S, Krepart G: Dose vs response of tetrahydroannabinol (THC) vs prochlorperazine as chemotherapy antiemetics. Proc Am Soc Clin Oncol 1981; 22: 422.
    • (1981) Proc Am Soc Clin Oncol , vol.22 , pp. 422
    • Levitt, M.1    Wilson, A.2    Bowman, D.3    Faiman, C.4    Kemel, S.5    Krepart, G.6
  • 53
    • 0018969807 scopus 로고
    • Antiemetic effect of tetrahydrocannabinol compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis
    • Orr LE, McKernan JF, Bloome B: Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis. Arch Int Med 1980; 140: 1431-33.
    • (1980) Arch Int Med , vol.140 , pp. 1431-1433
    • Orr, L.E.1    McKernan, J.F.2    Bloome, B.3
  • 54
    • 0018922982 scopus 로고
    • Antiemetics in patients receiving chemotherapy for cancer. A randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine
    • Sallan SE, Cronin C, Zelen M, Zinberg NE: Antiemetics in patients receiving chemotherapy for cancer. A randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. N Engl J Med 1980; 302: 135-8.
    • (1980) N Engl J Med , vol.302 , pp. 135-138
    • Sallan, S.E.1    Cronin, C.2    Zelen, M.3    Zinberg, N.E.4
  • 55
    • 0016801115 scopus 로고
    • Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy
    • Sallan SE, Zinberg NE, Frei E: Antiemetic effect of delta-9- tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med 1975; 293: 795-7.
    • (1975) N Engl J Med , vol.293 , pp. 795-797
    • Sallan, S.E.1    Zinberg, N.E.2    Frei, E.3
  • 58
    • 33947356563 scopus 로고    scopus 로고
    • Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting
    • Meiri E, Jhangiani H, Vredenburgh JJ, et al.: Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin 2007; 23: 533-43.
    • (2007) Curr Med Res Opin , vol.23 , pp. 533-543
    • Meiri, E.1    Jhangiani, H.2    Vredenburgh, J.J.3
  • 59
    • 78649287164 scopus 로고    scopus 로고
    • Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting
    • Duran M, Pérez E, Abanades S, et al.: Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br J Clin Pharmacol 2010; 70: 656-63.
    • (2010) Br J Clin Pharmacol , vol.70 , pp. 656-663
    • Duran, M.1    Pérez, E.2    Abanades, S.3
  • 60
    • 0021052856 scopus 로고
    • Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy
    • Ahmedzai S, Carlyle DL, Clader IT, Moran F: Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. Br J Cancer 1983; 48: 657-63.
    • (1983) Br J Cancer , vol.48 , pp. 657-663
    • Ahmedzai, S.1    Carlyle, D.L.2    Clader, I.T.3    Moran, F.4
  • 61
    • 0023266519 scopus 로고
    • Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: A double-blind, crossover trial
    • Chan HS, Correia JA, MacLeod SM: Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial. Pediatrics 1987; 79: 946-52.
    • (1987) Pediatrics , vol.79 , pp. 946-952
    • Chan, H.S.1    Correia, J.A.2    MacLeod, S.M.3
  • 62
    • 0022597720 scopus 로고
    • Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatinum: A double blind study
    • Crawford SM, Buckman R: Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatinum: a double blind study. Med Oncol Tumour Pharmacother 1986; 3: 39-42.
    • (1986) Med Oncol Tumour Pharmacother , vol.3 , pp. 39-42
    • Crawford, S.M.1    Buckman, R.2
  • 63
    • 0023884902 scopus 로고
    • A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues
    • Cunningham D, Bradley CJ, Forrest GJ, et al.: A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues. Eur J Can Clin Oncol 1988; 24: 685-9.
    • (1988) Eur J Can Clin Oncol , vol.24 , pp. 685-689
    • Cunningham, D.1    Bradley, C.J.2    Forrest, G.J.3
  • 64
    • 0022610744 scopus 로고
    • Nabilone: An alternative antiemetic for cancer chemotherapy
    • Dalzell AM, Bartlett H, Lilleyman JS: Nabilone: An alternative antiemetic for cancer chemotherapy. Arch Dis Child 1986; 61: 502-5.
    • (1986) Arch Dis Child , vol.61 , pp. 502-505
    • Dalzell, A.M.1    Bartlett, H.2    Lilleyman, J.S.3
  • 65
    • 0019605643 scopus 로고
    • Nabilone: An effective antiemetic in patients receiving cancer chemotherapy
    • Einhorn LH, Nagy C, Furnas B, Williams SD: Nabilone: an effective antiemetic in patients receiving cancer chemotherapy. J Clin Pharmacol 1981; 21(8-9 Suppl): 64-9.
    • (1981) J Clin Pharmacol , vol.21 , Issue.8-9 SUPPL. , pp. 64-69
    • Einhorn, L.H.1    Nagy, C.2    Furnas, B.3    Williams, S.D.4
  • 66
    • 0020510263 scopus 로고
    • Randomized comparative trial of a new antiemetic: Nabilone, in cancer patients treated with cisplatin
    • George M, Pejovic MH, Thuaire M, Kramar A, Wolff JP: Random - ized comparative trial of a new anti-emetic: nabilone, in cancer patients treated with cisplatin. Biomed Pharmacother 1983; 37: 24-7.
    • (1983) Biomed Pharmacother , vol.37 , pp. 24-27
    • George, M.1    Pejovic, M.H.2    Thuaire, M.3    Kramar, A.4    Wolff, J.P.5
  • 67
    • 0018747577 scopus 로고
    • Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy
    • Herman TS, Einhorn LH, Jones SE, et al.: Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med 1979; 300: 1295-7.
    • (1979) N Engl J Med , vol.300 , pp. 1295-1297
    • Herman, T.S.1    Einhorn, L.H.2    Jones, S.E.3
  • 68
    • 0020283655 scopus 로고
    • A double-blind, controlled trial of nabilone vs prochlorperazine for refractory emesis induced by cancer chemotherapy
    • Johansson R, Kilkku P, Groenroos M: A double-blind, controlled trial of nabilone vs prochlorperazine for refractory emesis induced by cancer chemotherapy. Can Treat Rev 1982; 9: 25-33.
    • (1982) Can Treat Rev , vol.9 , pp. 25-33
    • Johansson, R.1    Kilkku, P.2    Groenroos, M.3
  • 69
    • 0020261715 scopus 로고
    • A multi-institutional phase III study of nabilone vs placebo in chemotherapy-induced nausea and vomiting
    • Jones SE, Durant JR, Greco FA, Robertone A: A multi-institutional phase III study of nabilone vs placebo in chemotherapy-induced nausea and vomiting. Can Treat Rev 1982; 9: 45-8.
    • (1982) Can Treat Rev , vol.9 , pp. 45-48
    • Jones, S.E.1    Durant, J.R.2    Greco, F.A.3    Robertone, A.4
  • 70
    • 0020309510 scopus 로고
    • Nabilone vs placebo in the treatment of chemotherapyinduced nausea and vomiting in cancer patients
    • Levitt M: Nabilone vs placebo in the treatment of chemotherapyinduced nausea and vomiting in cancer patients. Can Treat Rev 1982; 9(suppl B): 49-53.
    • (1982) Can Treat Rev , vol.9 , Issue.SUPPL. B , pp. 49-53
    • Levitt, M.1
  • 72
    • 0022576585 scopus 로고
    • Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy
    • Niederle N, Schutte J, Schmidt CG: Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy. Klin Wochenschr 1986; 64: 362-5.
    • (1986) Klin Wochenschr , vol.64 , pp. 362-365
    • Niederle, N.1    Schutte, J.2    Schmidt, C.G.3
  • 73
    • 0022371079 scopus 로고
    • A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy
    • Niiranen Aila, Mattson K: A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy. Am J Clin Oncol 1985; 8: 336-40.
    • (1985) Am J Clin Oncol , vol.8 , pp. 336-340
    • Aila, N.1    Mattson, K.2
  • 74
    • 0022547598 scopus 로고
    • Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis
    • Pomeroy M, Fennelly JJ, Towers M: Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis. Can Chemother Pharmacol 1986; 17: 285-8.
    • (1986) Can Chemother Pharmacol , vol.17 , pp. 285-288
    • Pomeroy, M.1    Fennelly, J.J.2    Towers, M.3
  • 75
    • 0018899177 scopus 로고
    • Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis
    • Steele N, Gralla RJ, Braun Jr DW, Young CW: Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis. Can Treat Rep 1980; 64: 219-24.
    • (1980) Can Treat Rep , vol.64 , pp. 219-224
    • Steele, N.1    Gralla, R.J.2    Braun Jr., D.W.3    Young, C.W.4
  • 76
    • 0020285148 scopus 로고
    • Double-blind, randomized, crossover trial of nabilone vs placebo in cancer chemotherapy
    • Wada JK, Bogdon DL, Gunnell JC, Hum GJ, Gota CH, Rieth TE: Double-blind, randomized, crossover trial of nabilone vs. placebo in cancer chemotherapy. Cancer Treatment Rev 1982; 9(Suppl B): 39-44.
    • (1982) Cancer Treatment Rev , vol.9 , Issue.SUPPL. B , pp. 39-44
    • Wada, J.K.1    Bogdon, D.L.2    Gunnell, J.C.3    Hum, G.J.4    Gota, C.H.5    Rieth, T.E.6
  • 77
    • 0021913458 scopus 로고
    • Antiemetic efficacy of levonantradol compared to delta-9- tetrahydrocannabinol for chemotherapy-induced nausea and vomiting
    • Citron ML, Herman TS, Vreeland F, Krasnow SH, Fossieck BE Jr: Antiemetic efficacy of levonantradol compared to delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting. Cancer Treat Rep 1985; 69: 109-12.
    • (1985) Cancer Treat Rep , vol.69 , pp. 109-112
    • Citron, M.L.1    Herman, T.S.2    Vreeland, F.3    Krasnow, S.H.4    Fossieck Jr., B.E.5
  • 79
    • 0020576410 scopus 로고
    • A randomised multicentre single blind comparison of a cannabinoid anti-emetic (levonantradol) with ychlorpromazine in patients receiving their first cytotoxic chemotherapy
    • Hutcheon AW, Palmer JB, Soukop M, et al.: A randomised multicentre single blind comparison of a cannabinoid anti-emetic (levonantradol) with ychlorpromazine in patients receiving their first cytotoxic chemotherapy. Eur J Can Clin Oncol 1983; 19: 1087-90.
    • (1983) Eur J Can Clin Oncol , vol.19 , pp. 1087-1090
    • Hutcheon, A.W.1    Palmer, J.B.2    Soukop, M.3
  • 80
    • 0021688369 scopus 로고
    • Dose ranging evalua - Tion of the antiemetic efficacy and toxicity of intramuscular levonantradol in cancer subjects with chemotherapy-induced emesis
    • Stambaugh Jr JE, McAdams J, Vreeland F: Dose ranging evalua - tion of the antiemetic efficacy and toxicity of intramuscular levonantradol in cancer subjects with chemotherapy-induced emesis. Int J Clin Pharmacol Res 1984; 24: 480-5.
    • (1984) Int J Clin Pharmacol Res , vol.24 , pp. 480-485
    • Stambaugh Jr., J.E.1    McAdams, J.2    Vreeland, F.3
  • 81
    • 33745515076 scopus 로고    scopus 로고
    • American society of clinical oncology guideline for antiemetics in oncology: Update 2006
    • American Society of Clinical Oncology
    • American Society of Clinical Oncology, Kris MG, Hesketh PJ, et al.: American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006 J Clin Oncol 2006; 24 2932-47
    • (2006) J Clin Oncol , vol.24 , pp. 2932-2947
    • Kris, M.G.1    Hesketh, P.J.2
  • 82
    • 27144517504 scopus 로고    scopus 로고
    • Antiemesis, V.3
    • National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Antiemesis, V.3.2008. Available at: www.nccn.org/professionals/ physician-gls/PDF/antiemesis.pdf.
    • (2008) NCCN Clinical Practice Guidelines in Oncology
  • 83
    • 0027200985 scopus 로고
    • Effect of dronabinol on nutritional status in HIV infection
    • Struwe M, Kaempfer SH, Geiger CJ, et al.: Effect of dronabinol on nutritional status in HIV infection. Ann Pharmacother 1993; 27: 827-31.
    • (1993) Ann Pharmacother , vol.27 , pp. 827-831
    • Struwe, M.1    Kaempfer, S.H.2    Geiger, C.J.3
  • 84
    • 0028935579 scopus 로고
    • Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS
    • Beal JE, Olson R, Laubenstein L, et al.: Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Sympt Manag 1995; 10: 89-97.
    • (1995) J Pain Sympt Manag , vol.10 , pp. 89-97
    • Beal, J.E.1    Olson, R.2    Laubenstein, L.3
  • 85
    • 8044242331 scopus 로고    scopus 로고
    • The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome
    • Timpone JG, Wright DJ, Li N, et al.: The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syn - drome. AIDS Res Hum Retroviruses 1997; 13: 305-15.
    • (1997) AIDS Res Hum Retroviruses , vol.13 , pp. 305-315
    • Timpone, J.G.1    Wright, D.J.2    Li, N.3
  • 86
    • 78651301281 scopus 로고    scopus 로고
    • Efficacy and tolerability of high-dose dronabinol maintenance in HIV-positive marijuana smokers: A controlled laboratory study
    • Bedi G, Foltin RW, Gunderson EW, et al.: Efficacy and tolerability of high-dose dronabinol maintenance in HIV-positive marijuana smokers: a controlled laboratory study. Psychopharmacology 2010; 212: 675-86.
    • (2010) Psychopharmacology , vol.212 , pp. 675-686
    • Bedi, G.1    Foltin, R.W.2    Gunderson, E.W.3
  • 87
    • 0141677644 scopus 로고    scopus 로고
    • Short-term effects of cannabinoids in patients with HIV-1 infection: A randomized, placebo-controlled clinical trial
    • Abrams DI, Hilton JF, Leiser RJ, et al.: Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann Intern Med 2003; 139: 258-66.
    • (2003) Ann Intern Med , vol.139 , pp. 258-266
    • Abrams, D.I.1    Hilton, J.F.2    Leiser, R.J.3
  • 88
    • 26644474134 scopus 로고    scopus 로고
    • Dronabinol and marijuana in HIV(+) marijuana smokers: Acute effects on caloric intake and mood
    • Haney M, Rabkin J, Gunderson E, Foltin RW: Dronabinol and marijuana in HIV(+) marijuana smokers: acute effects on caloric intake and mood. Psychopharmacology 2005; 181: 170-8.
    • (2005) Psychopharmacology , vol.181 , pp. 170-178
    • Haney, M.1    Rabkin, J.2    Gunderson, E.3    Foltin, R.W.4
  • 89
    • 34548057495 scopus 로고    scopus 로고
    • Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake, mood, and sleep
    • Haney M, Gunderson EW, Rabkin J, et al.: Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake, mood, and sleep. J Acquir Immune Defic Syndr 2007; 45: 545-54.
    • (2007) J Acquir Immune Defic Syndr , vol.45 , pp. 545-554
    • Haney, M.1    Gunderson, E.W.2    Rabkin, J.3
  • 90
    • 0037080279 scopus 로고    scopus 로고
    • Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: A North Central Cancer Treatment Group study
    • Jatoi A, Windschitl HE, Loprinzi CL, et al.: Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 2002; 20: 567-73.
    • (2002) J Clin Oncol , vol.20 , pp. 567-573
    • Jatoi, A.1    Windschitl, H.E.2    Loprinzi, C.L.3
  • 91
    • 0002135271 scopus 로고
    • Delta-9-tetrahydrocannabinol as an effective antidepressant and appetite-stimulating agent in advanced cancer patients
    • Braude MC, Szara S (eds.), New York: Raven Press
    • Regelson W, Butler JR, Schulz J, et al.: Delta-9-tetrahydrocannabinol as an effective antidepressant and appetite-stimulating agent in advanced cancer patients. In: Braude MC, Szara S (eds.): Pharmacology of marihuana. Vol 2. New York: Raven Press 1976; 763-76.
    • (1976) Pharmacology of Marihuana , vol.2 , pp. 763-776
    • Regelson, W.1    Butler, J.R.2    Schulz, J.3
  • 92
    • 79958253782 scopus 로고    scopus 로고
    • Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: Results of a randomized, double-blind, placebocontrolled pilot trial
    • Brisbois TD, de Kock IH, Watanabe SM, et al.: Delta-9- tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebocontrolled pilot trial. Ann Oncol 2011; 22: 2086-93.
    • (2011) Ann Oncol , vol.22 , pp. 2086-2093
    • Brisbois, T.D.1    De Kock, I.H.2    Watanabe, S.M.3
  • 93
    • 33746793870 scopus 로고    scopus 로고
    • Comparison of orally administered cannabis extract and delta- 9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: A multicenter, phase III, random - Ized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia- Study-Group
    • Cannabis-In-Cachexia-Study-Group, Strasser F, Luftner D, et al.: Comparison of orally administered cannabis extract and delta- 9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, random - ized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia- Study-Group. J Clin Oncol 2006; 24: 3394-400.
    • (2006) J Clin Oncol , vol.24 , pp. 3394-3400
    • Strasser, F.1    Luftner, D.2
  • 94
    • 0030886734 scopus 로고    scopus 로고
    • Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease
    • Volicer L, Stelly M, Morris J, McLaughlin J, Volicer BJ: Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int J Geriatr Psychiatry 1997; 12: 913-9.
    • (1997) Int J Geriatr Psychiatry , vol.12 , pp. 913-919
    • Volicer, L.1    Stelly, M.2    Morris, J.3    McLaughlin, J.4    Volicer, B.J.5
  • 95
    • 4043096916 scopus 로고    scopus 로고
    • Does the cannabinoid dro - Nabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial
    • Svendsen KB, Jensen TS, Bach FW: Does the cannabinoid dro - nabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004; 329: 253.
    • (2004) BMJ , vol.329 , pp. 253
    • Svendsen, K.B.1    Jensen, T.S.2    Bach, F.W.3
  • 96
    • 77957567663 scopus 로고    scopus 로고
    • Effect of dronabinol on central neuropathic pain after spinal cord injury: A pilot study
    • Rintala DH, Fiess RN, Tan G, Holmes SA, Bruel BM: Effect of dronabinol on central neuropathic pain after spinal cord injury: a pilot study. Am J Phys Med Rehabil 2010; 89: 840-8.
    • (2010) Am J Phys Med Rehabil , vol.89 , pp. 840-848
    • Rintala, D.H.1    Fiess, R.N.2    Tan, G.3    Holmes, S.A.4    Bruel, B.M.5
  • 97
    • 0345669751 scopus 로고    scopus 로고
    • A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms
    • Wade DT, Robson P, House H, Makela P, Aram J: A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003; 17: 18-26.
    • (2003) Clin Rehabil , vol.17 , pp. 18-26
    • Wade, D.T.1    Robson, P.2    House, H.3    Makela, P.4    Aram, J.5
  • 98
    • 9244223576 scopus 로고    scopus 로고
    • Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: Results of a randomised controlled trial
    • Berman JS, Symonds C, Birch R: Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain 2004; 112: 299-306.
    • (2004) Pain , vol.112 , pp. 299-306
    • Berman, J.S.1    Symonds, C.2    Birch, R.3
  • 99
    • 33750618230 scopus 로고    scopus 로고
    • Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticityrelated pain : A double-blind placebo-controlled cross-over trial
    • Wissel J, Haydn T, Müller J, et al.: Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticityrelated pain : a double-blind placebo-controlled cross-over trial. J Neurol 2006; 253: 1337-41.
    • (2006) J Neurol , vol.253 , pp. 1337-1341
    • Wissel, J.1    Haydn, T.2    Müller, J.3
  • 100
    • 38949107918 scopus 로고    scopus 로고
    • Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: Randomised, crossover, double blind study
    • Frank B, Serpell MG, Hughes J, Matthews JN, Kapur D: Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, cross - over, double blind study. BMJ 2008; 336: 199-201.
    • (2008) BMJ , vol.336 , pp. 199-201
    • Frank, B.1    Serpell, M.G.2    Hughes, J.3    Matthews, J.N.4    Kapur, D.5
  • 101
    • 25444530723 scopus 로고    scopus 로고
    • Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis
    • Rog DJ, Nurmikko TJ, Friede T, Young CA: Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005; 65: 812-9.
    • (2005) Neurology , vol.65 , pp. 812-819
    • Rog, D.J.1    Nurmikko, T.J.2    Friede, T.3    Young, C.A.4
  • 102
    • 36348982602 scopus 로고    scopus 로고
    • Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trial
    • Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D: Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain 2007; 133: 210-20.
    • (2007) Pain , vol.133 , pp. 210-220
    • Nurmikko, T.J.1    Serpell, M.G.2    Hoggart, B.3    Toomey, P.J.4    Morlion, B.J.5    Haines, D.6
  • 103
    • 74249110995 scopus 로고    scopus 로고
    • Randomised Placebo Controlled Double Blind Clinical Trial of Cannabis Based Medicinal Product (Sativex) in Painful Diabetic Neuropathy: Depression is a Major Confounding Factor
    • Selvarajah D, Gandhi R, Emery CJ, Tesfaye S: Randomised Placebo Controlled Double Blind Clinical Trial of Cannabis Based Medicinal Product (Sativex) in Painful Diabetic Neuropathy: Depression is a Major Confounding Factor. Diabetes Care 2010; 33: 128-30.
    • (2010) Diabetes Care , vol.33 , pp. 128-130
    • Selvarajah, D.1    Gandhi, R.2    Emery, C.J.3    Tesfaye, S.4
  • 104
    • 33847013770 scopus 로고    scopus 로고
    • Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial
    • Abrams DI, Jay CA, Shade SB, et al.: Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial. Neurology 2007; 68: 515-21.
    • (2007) Neurology , vol.68 , pp. 515-521
    • Abrams, D.I.1    Jay, C.A.2    Shade, S.B.3
  • 105
    • 44249115281 scopus 로고    scopus 로고
    • A randomized, placebocontrolled, crossover trial of cannabis cigarettes in neuropathic pain
    • Wilsey B, Marcotte T, Tsodikov A, et al.: A randomized, placebocontrolled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain 2008; 9: 506-21.
    • (2008) J Pain , vol.9 , pp. 506-521
    • Wilsey, B.1    Marcotte, T.2    Tsodikov, A.3
  • 106
    • 58149463198 scopus 로고    scopus 로고
    • Smoked medicinal cannabis for neuropathic pain in HIV: A randomized, crossover clinical trial
    • Ellis RJ, Toperoff W, Vaida F, et al.: Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology 2009; 34: 672-80.
    • (2009) Neuropsychopharmacology , vol.34 , pp. 672-680
    • Ellis, R.J.1    Toperoff, W.2    Vaida, F.3
  • 107
    • 77958035149 scopus 로고    scopus 로고
    • Smoked cannabis for chronic neuropathic pain: A randomized controlled trial
    • Ware MA, Wang T, Shapiro S, et al.: Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ 2010; 182: 694-701.
    • (2010) CMAJ , vol.182 , pp. 694-701
    • Ware, M.A.1    Wang, T.2    Shapiro, S.3
  • 108
    • 0141593561 scopus 로고    scopus 로고
    • Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: A randomized controlled trial
    • Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U: Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA 2003; 290: 1757-6.
    • (2003) JAMA , vol.290 , pp. 1757-1766
    • Karst, M.1    Salim, K.2    Burstein, S.3    Conrad, I.4    Hoy, L.5    Schneider, U.6
  • 110
    • 0016527783 scopus 로고
    • The analgesic properties of delta-9-tetrahydrocannabinol and codeine
    • Noyes R, Brunk ST, Avery DH, Canter A: The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther 1975; 18: 84-9.
    • (1975) Clin Pharmacol Ther , vol.18 , pp. 84-89
    • Noyes, R.1    Brunk, S.T.2    Avery, D.H.3    Canter, A.4
  • 111
    • 75949093107 scopus 로고    scopus 로고
    • Multicenter, double-blind, randomized, placebo- controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD Extract and THC extract in patients with intractable cancer-related pain
    • Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT: Multicenter, double-blind, randomized, placebo- controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD Extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage 2010; 39: 167-79.
    • (2010) J Pain Symptom Manage , vol.39 , pp. 167-179
    • Johnson, J.R.1    Burnell-Nugent, M.2    Lossignol, D.3    Ganae-Motan, E.D.4    Potts, R.5    Fallon, M.T.6
  • 112
    • 0018090510 scopus 로고
    • Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain
    • Staquet M, Gantt C, Machin D: Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clin Pharmacol Ther 1978; 23: 397-401.
    • (1978) Clin Pharmacol Ther , vol.23 , pp. 397-401
    • Staquet, M.1    Gantt, C.2    MacHin, D.3
  • 114
    • 29844435136 scopus 로고    scopus 로고
    • Preliminary assessment of the efficacy, tolerability and safety of a cannabisbased medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis
    • Blake DR, Robson P, Ho M, Jubb RW, McCabe CS: Preliminary assessment of the efficacy, tolerability and safety of a cannabisbased medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology 2006; 45: 50-2.
    • (2006) Rheumatology , vol.45 , pp. 50-52
    • Blake, D.R.1    Robson, P.2    Ho, M.3    Jubb, R.W.4    McCabe, C.S.5
  • 115
    • 38349102259 scopus 로고    scopus 로고
    • Nabilone for the treatment of pain in fibromyalgia
    • Skrabek RQ, Galimova L, Ethans K, Perry D: Nabilone for the treatment of pain in fibromyalgia. J Pain 2008; 9: 164-73.
    • (2008) J Pain , vol.9 , pp. 164-173
    • Skrabek, R.Q.1    Galimova, L.2    Ethans, K.3    Perry, D.4
  • 116
    • 76249123626 scopus 로고    scopus 로고
    • The effects of nabi - Lone on sleep in fibromyalgia: Results of a randomized controlled trial
    • Ware MA, Fitzcharles MA, Joseph L, Shir Y: The effects of nabi - lone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg 2010; 110: 604-10.
    • (2010) Anesth Analg , vol.110 , pp. 604-610
    • Ware, M.A.1    Fitzcharles, M.A.2    Joseph, L.3    Shir, Y.4
  • 117
    • 39549091694 scopus 로고    scopus 로고
    • Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy
    • Narang S, Gibson D, Wasan AD, et al.: Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. J Pain 2008; 9: 254-64.
    • (2008) J Pain , vol.9 , pp. 254-264
    • Narang, S.1    Gibson, D.2    Wasan, A.D.3
  • 118
    • 2342613658 scopus 로고    scopus 로고
    • Initial experiences with medicinal extracts of cannabis for chronic pain: Results from 34 'N of 1' studies
    • Notcutt W, Price M, Miller R, et al.: Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies. Anaesthesia 2004; 59: 440-52.
    • (2004) Anaesthesia , vol.59 , pp. 440-452
    • Notcutt, W.1    Price, M.2    Miller, R.3
  • 119
    • 33751425461 scopus 로고    scopus 로고
    • Evaluation of herbal cannabis characteristics by medical users: A randomized trial
    • Ware MA, Ducruet T, Robinson AR: Evaluation of herbal cannabis characteristics by medical users: a randomized trial. Harm Reduct J 2006; 3: 32.
    • (2006) Harm Reduct J , vol.3 , pp. 32
    • Ware, M.A.1    Ducruet, T.2    Robinson, A.R.3
  • 120
    • 33746332378 scopus 로고    scopus 로고
    • Nutzen einer Add-On-Therapie mit dem synthetischen Cannabinomimetikum Nabilone bei Patienten mit chronischen Schmerzzuständen - eine randomisierte kontrollierte Studie
    • Pinsger M, Schimetta W, Volc D, Hiermann E, Riederer F, Polz W: Nutzen einer Add-On-Therapie mit dem synthetischen Cannabinomimetikum Nabilone bei Patienten mit chronischen Schmerzzuständen - eine randomisierte kontrollierte Studie. Wien Klin Wochenschr 2006; 118: 327-35.
    • (2006) Wien Klin Wochenschr , vol.118 , pp. 327-335
    • Pinsger, M.1    Schimetta, W.2    Volc, D.3    Hiermann, E.4    Riederer, F.5    Polz, W.6
  • 121
    • 0017349888 scopus 로고
    • Effects of intravenous tetrahydrocannabinol on experimental and surgical pain: Psychological correlates of the analgesic response
    • Raft D, Gregg J, Ghia J, Harris L: Effects of intravenous tetrahydrocannabinol on experimental and surgical pain: psychological correlates of the analgesic response. Clin Pharmacol Ther 1977; 21: 26-33.
    • (1977) Clin Pharmacol Ther , vol.21 , pp. 26-33
    • Raft, D.1    Gregg, J.2    Ghia, J.3    Harris, L.4
  • 122
    • 0142227167 scopus 로고    scopus 로고
    • Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain
    • Buggy DJ, Toogood L, Maric S, Sharpe P, Lambert DG, Rowbotham DJ: Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain. Pain 2003; 106: 169-72.
    • (2003) Pain , vol.106 , pp. 169-172
    • Buggy, D.J.1    Toogood, L.2    Maric, S.3    Sharpe, P.4    Lambert, D.G.5    Rowbotham, D.J.6
  • 123
    • 33646235388 scopus 로고    scopus 로고
    • Delta-9-tetrahydrocannabinol and the opioid receptor agonist piritramide do not act synergistically in postoperative pain
    • Seeling W, Kneer L, Buchele B, et al.: Delta-9-tetrahydrocannabinol and the opioid receptor agonist piritramide do not act synergistically in postoperative pain. Anaesthesist 2006; 55: 391-400.
    • (2006) Anaesthesist , vol.55 , pp. 391-400
    • Seeling, W.1    Kneer, L.2    Buchele, B.3
  • 124
    • 33646769573 scopus 로고    scopus 로고
    • A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management
    • Holdcroft A, Maze M, Dore C, Tebbs S, Thompson S: A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. Anesthesiology 2006; 104: 1040-6.
    • (2006) Anesthesiology , vol.104 , pp. 1040-1046
    • Holdcroft, A.1    Maze, M.2    Dore, C.3    Tebbs, S.4    Thompson, S.5
  • 125
    • 33748868111 scopus 로고    scopus 로고
    • Effects of nabilone, a synthetic cannabinoid, on postoperative pain
    • Beaulieu P: Effects of nabilone, a synthetic cannabinoid, on postoperative pain. Can J Anaesth 2006; 53: 769-75.
    • (2006) Can J Anaesth , vol.53 , pp. 769-775
    • Beaulieu, P.1
  • 126
    • 0019605641 scopus 로고
    • Evaluation of intramuscular levonantradol and placebo in acute postoperative pain
    • Jain AK, Ryan JR, McMahon FG, Smith G: Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. J Clin Pharmacol 1981; 21(suppl 8-9): 320-6.
    • (1981) J Clin Pharmacol , vol.21 , Issue.SUPPL. 8 AND 9 , pp. 320-326
    • Jain, A.K.1    Ryan, J.R.2    McMahon, F.G.3    Smith, G.4
  • 127
    • 0019492496 scopus 로고
    • A study of levonantradol, a cannabinol derivative, for analgesia in post operative pain
    • Kantor TG, Hopper M: A study of levonantradol, a cannabinol derivative, for analgesia in post operative pain. Pain 1981; (suppl): S37.
    • (1981) Pain , Issue.SUPPL.
    • Kantor, T.G.1    Hopper, M.2
  • 128
    • 80052718419 scopus 로고    scopus 로고
    • A randomized, controlled study to investigate the analgesic efficacy of single doses of the cannabinoid receptor-2 agonist GW842166, ibuprofen or placebo in patients with acute pain following third molar tooth extraction
    • Ostenfeld T, Price J, Albanese M, et al.: A randomized, controlled study to investigate the analgesic efficacy of single doses of the cannabinoid receptor-2 agonist GW842166, ibuprofen or placebo in patients with acute pain following third molar tooth extraction. Clin J Pain 2011; 27: 668-76.
    • (2011) Clin J Pain , vol.27 , pp. 668-676
    • Ostenfeld, T.1    Price, J.2    Albanese, M.3
  • 129
    • 33750037938 scopus 로고    scopus 로고
    • The effect of cannabis on urge incontinence in patients with multiple sclerosis: A multicentre, randomised placebo- controlled trial (CAMS-LUTS)
    • Freeman RM, Adekanmi O, Waterfield MR, Waterfield AE, Wright D, Zajicek J: The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo- controlled trial (CAMS-LUTS). Int Urogynecol J Pelvic Floor Dysfunct 2006; 17: 636-41.
    • (2006) Int Urogynecol J Pelvic Floor Dysfunct , vol.17 , pp. 636-641
    • Freeman, R.M.1    Adekanmi, O.2    Waterfield, M.R.3    Waterfield, A.E.4    Wright, D.5    Zajicek, J.6
  • 130
    • 4344585483 scopus 로고    scopus 로고
    • An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis
    • Brady CM, DasGupta R, Dalton C, Wiseman OJ, Berkley KJ, Fowler CJ: An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Multiple Sclerosis 2004; 10: 425-33.
    • (2004) Multiple Sclerosis , vol.10 , pp. 425-433
    • Brady, C.M.1    Dasgupta, R.2    Dalton, C.3    Wiseman, O.J.4    Berkley, K.J.5    Fowler, C.J.6
  • 131
    • 78349253181 scopus 로고    scopus 로고
    • Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis
    • Kavia RB, De Ridder D, Constantinescu CS, Stott CG, Fowler CJ: Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult Scler 2010; 16: 1349-59.
    • (2010) Mult Scler , vol.16 , pp. 1349-1359
    • Kavia, R.B.1    De Ridder, D.2    Constantinescu, C.S.3    Stott, C.G.4    Fowler, C.J.5
  • 132
    • 0036219901 scopus 로고    scopus 로고
    • Treatment of Tourette's syndrome with Δ9-tetrahydrocannabinol (THC): A random ized crossover trial
    • Müller-Vahl KR, Schneider U, Koblenz A, et al.: Treatment of Tourette's syndrome with Δ9-tetrahydrocannabinol (THC): a random ized crossover trial. Pharmacopsychiatry 2002; 35: 57-61.
    • (2002) Pharmacopsychiatry , vol.35 , pp. 57-61
    • Müller-Vahl, K.R.1    Schneider, U.2    Koblenz, A.3
  • 133
    • 0038710735 scopus 로고    scopus 로고
    • Δ9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial
    • Müller-Vahl KR, Schneider U, Prevedel H, et al.: Δ9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J Clin Psychiatry 2003; 64: 459-65.
    • (2003) J Clin Psychiatry , vol.64 , pp. 459-465
    • Müller-Vahl, K.R.1    Schneider, U.2    Prevedel, H.3
  • 134
    • 0001291621 scopus 로고    scopus 로고
    • The effects of the cannabinoid receptor agonist nabilone on L-DOPA induced dyskinesia in patients with idiopathic Parkinson's disease (PD)
    • Sieradzan KA, Fox SH, Dick J, Brotchie JM: The effects of the cannabinoid receptor agonist nabilone on L-DOPA induced dyskinesia in patients with idiopathic Parkinson's disease (PD). Movement Disorders 1998; 13(Suppl 2): 29.
    • (1998) Movement Disorders , vol.13 , Issue.SUPPL. 2 , pp. 29
    • Sieradzan, K.A.1    Fox, S.H.2    Dick, J.3    Brotchie, J.M.4
  • 135
    • 67649265233 scopus 로고    scopus 로고
    • Synthetic delta-9-tetrahydrocannabinol (dronabinol) can improve the symptoms of schizophrenia
    • Schwarcz G, Karajgi B, McCarthy R: Synthetic delta-9-tetrahydrocannabinol (dronabinol) can improve the symptoms of schizophrenia. J Clin Psychopharmacol 2009; 29: 255.
    • (2009) J Clin Psychopharmacol , vol.29 , pp. 255
    • Schwarcz, G.1    Karajgi, B.2    McCarthy, R.3
  • 136
    • 78649784793 scopus 로고    scopus 로고
    • Improvement in refractory psychosis with dronabinol: Four case reports
    • Schwarcz G, Karajgi B: Improvement in refractory psychosis with dronabinol: four case reports. J Clin Psychiatry 2010; 71: 1552-3.
    • (2010) J Clin Psychiatry , vol.71 , pp. 1552-1553
    • Schwarcz, G.1    Karajgi, B.2
  • 137
    • 0017095185 scopus 로고
    • Clinical studies of cannabis tolerance and dependence
    • Jones RT, Benowitz N, Bachman J: Clinical studies of cannabis tolerance and dependence. Ann N Y Acad Sci 1976; 282: 221-39.
    • (1976) Ann N y Acad Sci , vol.282 , pp. 221-239
    • Jones, R.T.1    Benowitz, N.2    Bachman, J.3
  • 138
    • 0018111446 scopus 로고
    • Biological aspects of cannabis use
    • Stefanis C: Biological aspects of cannabis use. NIDA Res Monogr 1978; 19: 149-78.
    • (1978) NIDA Res Monogr , vol.19 , pp. 149-178
    • Stefanis, C.1
  • 139
    • 0034943318 scopus 로고    scopus 로고
    • Tetrahydrocannabinol zur Therapie chronischer Schmerzen
    • Elsner F, Radbruch L, Sabatowski R: Tetrahydrocannabinol zur Therapie chronischer Schmerzen. Schmerz 2001; 15: 200-4.
    • (2001) Schmerz , vol.15 , pp. 200-204
    • Elsner, F.1    Radbruch, L.2    Sabatowski, R.3
  • 140
    • 84861456223 scopus 로고    scopus 로고
    • Reversible and regionally selective down regulation of brain cannabinoid CB(1) receptors in chronic daily cannabis smokers
    • Hirvonen J, Goodwin RS, Li CT, et al.: Reversible and regionally selective down regulation of brain cannabinoid CB(1) receptors in chronic daily cannabis smokers. Molecular Psychiatry 2012; 17, 642-49.
    • (2012) Molecular Psychiatry , vol.17 , pp. 642-649
    • Hirvonen, J.1    Goodwin, R.S.2    Li, C.T.3
  • 141
    • 21044453748 scopus 로고    scopus 로고
    • The effect of nabilone on neuropsychological functions related to driving ability: An extended case series
    • Kurzthaler I, Bodner T, Kemmler G, et al.: The effect of nabilone on neuropsychological functions related to driving ability: an extended case series. Hum Psychopharmacol 2005; 20: 291-3.
    • (2005) Hum Psychopharmacol , vol.20 , pp. 291-293
    • Kurzthaler, I.1    Bodner, T.2    Kemmler, G.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.